The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma

Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, Roberto Sabbatini, Ugo De Giorgi, Daniele Santini, Gaetano Facchini, Alessandra Mosca, Francesco Atzori, Paolo Zucali, Giuseppe Fornarini, Francesco Massari, Sebastiano Buti, Riccardo Ricotta, Cristina Masini, Ilaria Toscani, Elisa Biasco, Annalisa Guida, Cristian Lolli, Delia De LisiSabrina Rossetti, Carlo Terrone, Mario Scartozzi, Chiara Miggiano, Alessandro Pastorino, Melissa Bersanelli, Giulia Carlo-Stella, Carmine Pinto, Elisabetta Nobili, Franco Nolè, Giampaolo Tortora, Camillo Porta

Research output: Contribution to journalArticle

Abstract

We aimed to investigate the different outcomes in patients with metastatic renal cell carcinoma treated with second-line axitinib or everolimus after sunitinib. Patients treated in 16 oncological centres in Italy were included, and those receiving axitinib or everolimus from January 2013 onwards were analysed for outcomes. Descriptive statistical tests were used to highlight differences between groups. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Data on 634 patients with metastatic renal cell carcinoma treated with first-line sunitinib have been obtained. A total of 182 patients received a second-line therapy with everolimus (79 patients, 43%) or axitinib (103 patients, 57%), respectively. The median PFS was 4.6 [95% confidence (CI): 2.6-6.5] months for patients treated with everolimus and 5.5 (95% CI: 4.3-6.7) months for patients treated with axitinib (P=0.7). The median OS was 13.9 (95% CI: 10.4-17.4) months for patients treated with everolimus and 12.0 (95% CI: 7.9-16.2) months for patients treated with axitinib (P=0.3). No differences were found based on length of first-line treatment. Major limitations are the retrospective nature of the study and the lack of a prospective evaluation of the progression. This study reports no significantly differences between everolimus and axitinib in terms of both PFS and OS. Furthermore, the length of first-line treatment cannot be used as such a predictive factor and cannot suggest the use of a molecule compared with another.
Original languageEnglish
Pages (from-to)705-709
Number of pages5
JournalAnti-Cancer Drugs
Volume29
Issue number7
DOIs
Publication statusPublished - Aug 1 2018

    Fingerprint

Cite this

Iacovelli, R., Cossu Rocca, M., Galli, L., Sabbatini, R., De Giorgi, U., Santini, D., Facchini, G., Mosca, A., Atzori, F., Zucali, P., Fornarini, G., Massari, F., Buti, S., Ricotta, R., Masini, C., Toscani, I., Biasco, E., Guida, A., Lolli, C., ... Porta, C. (2018). The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anti-Cancer Drugs, 29(7), 705-709. https://doi.org/10.1097/CAD.0000000000000632